Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARY LOPRESTI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1700046885
CMS profile
382918
Location
NEWTON CENTRE, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$11.92

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $11.92 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $11.92 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARY LOPRESTI

NPI 1700046885 · CMS profile ID 382918

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEWTON CENTRE, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700046885?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARY LOPRESTI, NPI 1700046885, CMS profile ID 382918. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700046885?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARY LOPRESTI, NPI 1700046885, CMS profile ID 382918. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700046885?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARY LOPRESTI, NPI 1700046885, CMS profile ID 382918, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1700046885?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845875891 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $11.92 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $6,825.56 2
PY2020 Principal investigator $23,567.45 26
PY2019 Principal investigator $125,901.46 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

65 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,000.00 12/27/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671693077
Principal investigator 1 PFIZER INC. $2,900.00 12/06/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671693081
Principal investigator 1 Merck Sharp & Dohme Corporation $4,245.00 11/22/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 691526079
Principal investigator 1 Merck Sharp & Dohme Corporation $5,509.40 11/22/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 691526083
Principal investigator 1 PFIZER INC. $1,800.00 10/31/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671693079
Principal investigator 1 Merck Sharp & Dohme Corporation $2,657.20 10/25/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 691482363
Principal investigator 1 Merck Sharp & Dohme Corporation $10,722.20 10/23/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 691492769
Principal investigator 1 PFIZER INC. $1,200.00 09/30/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671693039
Principal investigator 1 PFIZER INC. $2,200.00 08/26/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671693123
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 08/22/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 691425347
Principal investigator 1 PFIZER INC. $4,600.00 07/30/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671693041
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649385
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649433
Principal investigator 1 PFIZER INC. $1,000.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649435
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649527
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649567
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649579
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649583
Principal investigator 1 PFIZER INC. $1,000.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649619
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649759
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649773
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649809
Principal investigator 1 Merck Sharp & Dohme Corporation $3,583.45 05/24/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 691320663
Principal investigator 1 PFIZER INC. $600.00 05/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649489
Principal investigator 1 PFIZER INC. $600.00 05/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649665
Principal investigator 1 PFIZER INC. $600.00 05/02/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649487
Principal investigator 1 PFIZER INC. $600.00 05/02/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649535
Principal investigator 1 PFIZER INC. $600.00 05/02/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649569
Principal investigator 1 PFIZER INC. $600.00 05/02/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649675
Principal investigator 1 PFIZER INC. $600.00 05/02/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649677
Principal investigator 1 PFIZER INC. $600.00 05/02/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649727
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649339
Principal investigator 1 PFIZER INC. $1,000.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649479
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649481
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649483
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649485
Principal investigator 1 PFIZER INC. $1,000.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649533
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649537
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649581
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649615
Principal investigator 1 PFIZER INC. $1,000.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649667
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649713
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649723
Principal investigator 1 PFIZER INC. $600.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649761
Principal investigator 1 PFIZER INC. $1,000.00 04/16/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649771
Principal investigator 1 Merck Sharp & Dohme Corporation $9,000.00 04/03/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 691320737
Principal investigator 1 Merck Sharp & Dohme Corporation $10,830.76 03/21/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) No dispute reported 06/30/2026 691291093
Principal investigator 1 Merck Sharp & Dohme Corporation $424.20 03/18/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 691320733
Principal investigator 1 PFIZER INC. $1,750.00 02/21/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649383
Principal investigator 1 PFIZER INC. $600.00 02/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649431
Principal investigator 1 PFIZER INC. $600.00 02/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649629
Principal investigator 1 PFIZER INC. $600.00 02/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649679
Principal investigator 1 PFIZER INC. $600.00 02/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649711
Principal investigator 1 PFIZER INC. $600.00 02/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649715
Principal investigator 1 PFIZER INC. $600.00 02/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649725
Principal investigator 1 PFIZER INC. $600.00 02/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649763
Principal investigator 1 PFIZER INC. $600.00 02/20/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649807
Principal investigator 1 Merck Sharp & Dohme Corporation $9,222.25 02/08/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 691320741
Principal investigator 1 PFIZER INC. $600.00 01/25/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649387
Principal investigator 1 PFIZER INC. $600.00 01/25/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649571
Principal investigator 1 PFIZER INC. $600.00 01/25/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649617
Principal investigator 1 PFIZER INC. $600.00 01/25/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649627
Principal investigator 1 PFIZER INC. $600.00 01/25/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649631
Principal investigator 1 PFIZER INC. $600.00 01/25/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 671649663
Principal investigator 1 Merck Sharp & Dohme Corporation $10,830.76 01/11/2019 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) No dispute reported 06/30/2026 691291089